Arch Therapeutics, INC

Arch Therapeutics announces the resignation of CFO Michael Abrams and the appointment of CEO Terrence Norchi as Principal Accounting Officer and Treasurer, effective February 3, 2025.

Arch Therapeutics finalized the tenth closing of its convertible notes offering on January 16, 2025, securing $125,000 in net proceeds for working capital and general corporate purposes.

Arch Therapeutics has completed the ninth closing of its convertible notes offering, securing approximately $100,000 in net proceeds.

Arch Therapeutics has amended several of its outstanding convertible promissory notes, extending their maturity dates from September 30, 2024, to November 30, 2024, and increasing the principal amount of some notes.

Arch Therapeutics has completed the eighth closing of its convertible notes offering, raising an additional $108,000 in net proceeds.

Arch Therapeutics has amended multiple promissory notes and a securities purchase agreement, extending maturity dates and increasing the maximum funding amount.

Arch Therapeutics saw a rise in revenue but also experienced a significant increase in net losses during the third quarter of 2024, primarily due to financing expenses.

Arch Therapeutics saw a rise in revenue during the second quarter of 2024, but ongoing losses and reliance on debt financing raise concerns about the company's ability to continue as a going concern.

Arch Therapeutics saw a significant increase in revenue in the first quarter of 2024 compared to the same period last year, but continues to operate at a loss and faces going concern challenges.

Arch Therapeutics has filed an amendment to its annual report to correct disclosures regarding beneficial ownership of shares by certain shareholders, directors, and officers.

Arch Therapeutics reports its fiscal year 2023 results, highlighting increased revenue but also significant losses and substantial doubt about its ability to continue as a going concern.

Arch Therapeutics is undertaking a unit offering to support its Cboe listing application and fuel the commercial rollout of its AC5 Advanced Wound System.